A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

Early screening for geographic atrophy may help slow progression to foveal involvement. Collaborating with optometrists on geographic atrophy care is beneficial for patients. Healio spoke with Yasha S ...

In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, ...

—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...

While pivotal research on therapies for neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA) focused on one condition or the other, retina specialists commonly encounter ...

While there is currently no cure for geographic atrophy, certain treatments, such as complement inhibitors, can help slow its progression by targeting immune system activity that damages the macula.

A novel outcome measure for geographic atrophy, the Geographic Atrophy Weighted-by-Acuity Index, aligned with best-corrected visual acuity, showing better correlation and predictive accuracy than the ...

Geographic atrophy (GA) is a condition that typically progresses slowly, with lesions expanding by about 1 square millimeter per year, leading to blind spots due to retinal deterioration. Treatment ...

Age is a major risk factor for geographic atrophy (GA). As the eyes age, natural defenses weaken, blood flow may decline, and waste removal may slow, allowing deposits called drusen to build up.